https://journal.riverpublishers.com/index.php/MCTM <div class="JL3"> <div class="journalboxline"> <div class="JL3"> <div class="journalboxline"> <p><strong>Molecular Cellular Therapy and Mechanism (MCTM)</strong></p> <p>MCTM is the frontline journal for molecular mechanisms, preclinical and clinical research and development of gene-, peptide-, protein-, and cell-based therapies, including target identification and validation, safety, toxicity, efficacy, efficiency, pharmacokinetics, metabolism, formulation, delivery, pharmacovigilance, biomarkers, new drug application. MCTM, central to clinical and translational medicine, will integrate genetics, cell biology, medicine, drug development, therapeutics, and biotechnology to improve the prognosis of patients</p> </div> </div> </div> </div> River Publishers en-US Molecular Cellular Therapy and Mechanism 2245-4586 https://journal.riverpublishers.com/index.php/MCTM/article/view/203 <p>MicroRNAs (miRNAs) are small non-coding RNA molecules that play critical roles in human disease. Several miRnome profiling studies have identified miRNAs deregulated in cancer and infectious diseases and miRNAs are also involved in regulation of the host response to infection. Thereby, the usage of miRNAs as biomarkers and potential treatments for both human and infectious diseases is under development. This review will provide insights into the contribution of miRNAs to pathogenesis and disease development and will present a general outline of the potential use of miRNAs as therapeutic tools.</p> Malak Haidar Gordon Langlsey Copyright (c) 2023 2023-03-27 2023-03-27 1–18 1–18 10.13052/mct2052-8426.811 https://journal.riverpublishers.com/index.php/MCTM/article/view/204 <p>MicroRNAs (miRNAs) are small noncoding RNAs that can function as either powerful tumor promoters or suppressors in numerous types of cancer. The ability of miRs to target multiple genes and biological signaling pathways has created intense interest in their potential clinical utility as predictive and diagnostic biomarkers, and as innovative therapeutic agents. Recently, accumulating preclinical studies have illustrated the feasibility of slowing tumor progression by either overexpressing tumor suppressive miRNAs, or by neutralizing the activities of oncogenic miRNAs in cell- and animal-based models of cancer. Here we highlight prominent miRNAs that may represent potential therapeutic targets in human malignancies, as well as review current technologies available for inactivating or restoring miRNA activity in clinical settings.</p> Molly Taylor William Sciemann Copyright (c) 2023 2023-03-27 2023-03-27 19–52 19–52 10.13052/mct2052-8426.812